Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Augmedix, Inc. AUGX NASDAQ

NASDAQ Capital Marke • Healthcare • Medical - Healthcare Information Services • US • USD

SharesGrow Score
40/100
2/7 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$2.67
+13.9%

Augmedix, Inc. (AUGX) is a Medical - Healthcare Information Services company in the Healthcare sector, currently trading at $2.35. It has a SharesGrow Score of 40/100, indicating a mixed investment profile with 2 out of 7 criteria passed.

Analyst consensus target is AUGX = $3 (+13.9% upside).

Financials: revenue is $45M, +39.7%/yr average growth. Net income is $19M (loss), growing at -14.4%/yr. Net profit margin is -42.7% (negative). Gross margin is 48% (+6.8 pp trend).

Balance sheet: total debt is $26M against $23M equity (Debt-to-Equity (D/E) ratio 1.11, moderate). Current ratio is 2.41 (strong liquidity). Debt-to-assets is 38.7%. Total assets: $67M.

Analyst outlook: 4 / 6 analysts rate AUGX as buy (67%) — moderate consensus.

SharesGrow 7-Criteria breakdown: Value 60/100 (Pass), Growth 58/100 (Partial), Past 0/100 (Fail), Health 50/100 (Partial), Moat 43/100 (Fail), Future 61/100 (Pass), Income 10/100 (Fail).

$2.67
▲ 13.86% Upside
Average Price Target
Based on 6 Wall Street analysts offering 12-month price targets for Augmedix, Inc., the average price target is $2.67, with a high forecast of $3.50, and a low forecast of $1.50.
Highest Price Target
$3.50
Average Price Target
$2.67
Lowest Price Target
$1.50

AUGX SharesGrow Score Overview

47/100
SharesGrow Score
Mixed signals — some strengths
View full scorecard →
VALUE 60/100
Valuation — P/E, PEG, Forward PEG
GROWTH 58/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 50/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 43/100
Gross margin is + market cap
FUTURE 61/100
Analyst outlook — as buy
INCOME 10/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — AUGX

✓
VALUE Pass
60/100
AUGX trades at a trailing Price-to-Earnings (P/E) of N/A (S&P 500 average ~25). Analyst consensus target is $3, implying +27.9% from the current price $2. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
~
GROWTH Partial
58/100
AUGX: +39.7%/yr revenue is, -14.4%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
~
HEALTH Partial
50/100
Balance sheet AUGX: Debt-to-Equity (D/E) ratio 1.11 (moderate), Current ratio is 2.41 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
43/100
AUGX: Gross margin is 48% (+6.8 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 43/100. ≥ 70 = Pass.
View details →
✓
FUTURE Pass
61/100
Analyst outlook: 4 / 6 analysts rate AUGX as buy (67%). Analyst consensus target is $3 (+27.9% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
✗
INCOME Fail
10/100
AUGX: Net profit margin is -42.7%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.
View details →

Stock Chart & Stats

Market Data
52-Week Range0.73-6.25
Volume23K
Avg Volume (30D)808.77K
Market Cap$115.91M
Beta (1Y)-0.19
Share Statistics
EPS (TTM)-0.44
Shares Outstanding$43.95M
IPO Date2021-03-31
Employees1,430
CEOEmmanuel Krakaris
Financial Highlights & Ratios
Revenue (TTM)$44.86M
Gross Profit$21.53M
EBITDA$-17.68M
Net Income$-19.17M
Operating Income$-18.78M
Total Cash$46.34M
Total Debt$25.85M
Net Debt$-20.5M
Total Assets$66.71M
Price / Earnings (P/E)-5.3
Price / Sales (P/S)2.58
Analyst Forecast
1Y Price Target$3.00
Target High$3.50
Target Low$1.50
Upside+27.9%
Rating ConsensusBuy
Analysts Covering6
Buy 67% Hold 33% Sell 0%
Price Target Summary
Company Info
CountryUS
ExchangeNASDAQ Capital Marke
CurrencyUSD
ISINUS05105P1075

Price Chart

Track all markets on TradingView
AUGX
Augmedix, Inc. ↗  ·  NASDAQ Capital Marke
Healthcare • Medical - Healthcare Information Services
0.73 52WK RANGE 6.25

People Also View

ELEV
ELEV
Elevation Oncology, Inc.
$0.37
-2.12%
 INAB
INAB
IN8bio, Inc.
$1.38
+2.22%
 ACON
ACON
Aclarion, Inc.
$3.17
-1.25%
 DRMA
DRMA
Dermata Therapeutics, Inc.
$1.25
-3.85%
 UTRS
UTRS
Minerva Surgical, Inc.
$0.00
+0.00%
 LLY
LLY
Eli Lilly and Company
$922.50
-0.76%
 JNJ
JNJ
Johnson & Johnson
$240.10
+0.90%
 ABBV
ABBV
AbbVie Inc.
$210.32
+1.86%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message